Note: This document contains side effect information about vancomycin. Some of the dosage forms listed on this page may not apply to the brand name Firvanq.
Applies to vancomycin: oral capsule, oral powder for solution
Other dosage forms:
Along with its needed effects, vancomycin (the active ingredient contained in Firvanq) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking vancomycin:
Incidence not known
Some side effects of vancomycin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to vancomycin: compounding powder, intravenous powder for injection, intravenous solution, oral capsule, oral powder for reconstitution, oral solution
The most commonly reported side effects include nausea, abdominal pain, and hypokalemia.
Chemical peritonitis occurred with intraperitoneal administration.
Mild gastrointestinal tract disturbances occurred with oral administration.
Very common (10% or more): Nausea (up to 17%), abdominal pain (up to 15%)
Common (1% to 10%): Vomiting, diarrhea, flatulence
Uncommon (0.1% to 1%): Mild gastrointestinal tract disturbances
Very rare (less than 0.01%): Pseudomembranous enterocolitis/colitis
Frequency not reported: Chemical peritonitis, constipation, indigestion, stomachache
Very common (10% or more): Hypokalemia (up to 13%)
Common (1% to 10%): Exanthema, pruritus, red man syndrome, redness of the face/upper arms, urticaria
Uncommon (0.1% to 1%): Erythema, itch
Rare (0.01% to 0.1%): Toxic epidermal necrolysis
Very rare (less than 0.01%): Exfoliative dermatitis, linear IgA bullous dermatosis, Lyell's syndrome, Stevens-Johnson syndrome
Frequency not reported: Acute generalized exanthematous pustulosis (AGEP), erythematous macular rash with intense pruritus over face/neck/upper body, rash, red neck
Common (1% to 10%): Decrease in blood pressure, flushing of the upper body, peripheral edema, phlebitis
Uncommon (0.1% to 1%): Thrombophlebitis
Rare (0.01% to 0.1%): Vasculitis
Very rare (less than 0.01%): Cardiac arrest
Frequency not reported: Bradycardia, cardiogenic shock, generalized flushing, hypotension, palpitations, substernal pressure, tachycardia
Postmarketing reports: Chest pain
Hypotension, bradycardia, cardiogenic shock, and cardiac arrest have occurred with rapid bolus administration.
Renal failure was most commonly characterized by increased serum creatinine levels or BUN concentrations.
Azotemia usually resolved upon discontinuation of treatment.
Common (1% to 10%): Increased serum creatinine, increased serum urea, nephrotoxicity, renal insufficiency
Rare (0.01% to 0.1%): Acute renal failure, interstitial nephritis
Frequency not reported: Acute kidney injury, Acute tubular necrosis, azotemia, blood urea nitrogen (BUN) concentrations increased, uremia, transient increased urea
Common (1% to 10%): Fatigue, mucosal inflammation, pyrexia
Uncommon (0.1% to 1%): Chills, fever, pain, permanent hearing loss, transient hearing loss
Rare (0.01% to 0.1%): Drug fever, ototoxicity, rigors, shivering, tinnitus
Common (1% to 10%): Dyspnea, stridor
Frequency not reported: Wheezing
Common (1% to 10%): Back pain
Rare (0.01% to 0.1%): Back and chest muscle pain and spasm
Common (1% to 10%): Headache
Rare (0.01% to 0.1%): Dizziness, vertigo
Common (1% to 10%): Urinary tract infection
Frequency not reported: Granular urinary casts
Uncommon (0.1% to 1%): Eosinophilia,
Rare (0.01% to 0.1%): Agranulocytosis, leukopenia, pancytopenia, reversible agranulocytosis, reversible neutropenia, thrombocytopenia
Frequency not reported: Anemia
Rare (0.01% to 0.1%): Anaphylactic reactions, anaphylaxis, hypersensitivity reactions
Frequency not reported: Anaphylactoid reaction
Rare (0.01% to 0.1%): Superinfection
Frequency not reported: Drug rash with eosinophilia and systemic symptoms (DRESS), non-susceptible organism overgrowth
Frequency not reported: Injection site inflammation, injection site pruritus, necrosis, tissue irritation
HORV occurred in patients given this drug via intracameral or intravitreal route during/after cataract surgery.
Frequency not reported: Hemorrhagic occlusive retinal vasculitis (HORV), permanent vision loss
Frequency not reported: Depression, insomnia
Frequency not reported: Transaminase elevations
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Firvanq